Technical Analysis for AZN - Astrazeneca Plc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Upper Bollinger Band Walk | Strength | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Crossed Above 200 DMA | Bullish | -0.60% | |
Expansion Breakout | Bullish Swing Setup | -0.60% | |
Stochastic Reached Overbought | Strength | -0.60% | |
Above Upper BB | Strength | -0.60% | |
Overbought Stochastic | Strength | -0.60% | |
Upper Bollinger Band Touch | Strength | -0.60% | |
Gapped Down | Weakness | 2.73% |
Alert | Time |
---|---|
Fell Below Upper Bollinger Band | 1 day ago |
Rose Above Previous Day's High | 1 day ago |
Up 2% | 2 days ago |
Upper Bollinger Band Resistance | 2 days ago |
Up 1 ATR | 2 days ago |
Free Daily (Stock) Chart Reading
Astrazeneca Plc Description
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Pharmaceutical Natural Sciences Science Life Sciences Disease Biopharmaceutical Oncology Pharmacy Pharmaceutical Industry Therapy Franchises Infection Respirator Therapies E Card Molecular Astrazeneca Neuroscience Heart Failure Kidney Disease Chronic Kidney Disease Södertälje Municipality
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 12389.2908 |
52 Week Low | 9461.5387 |
Average Volume | 2,614,449 |
200-Day Moving Average | 10551.89 |
50-Day Moving Average | 10270.72 |
20-Day Moving Average | 10334.70 |
10-Day Moving Average | 10414.00 |
Average True Range | 173.36 |
RSI (14) | 61.83 |
ADX | 13.96 |
+DI | 37.04 |
-DI | 18.96 |
Chandelier Exit (Long, 3 ATRs) | 10259.92 |
Chandelier Exit (Short, 3 ATRs) | 10502.08 |
Upper Bollinger Bands | 10703.84 |
Lower Bollinger Band | 9965.56 |
Percent B (%b) | 0.96 |
BandWidth | 7.14 |
MACD Line | 95.37 |
MACD Signal Line | 52.40 |
MACD Histogram | 42.9706 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 10837.00 | ||||
Resistance 3 (R3) | 10853.33 | 10816.67 | 10810.50 | ||
Resistance 2 (R2) | 10816.67 | 10776.17 | 10808.50 | 10801.66 | |
Resistance 1 (R1) | 10747.33 | 10751.16 | 10729.00 | 10731.00 | 10792.83 |
Pivot Point | 10710.67 | 10710.67 | 10701.50 | 10702.50 | 10710.67 |
Support 1 (S1) | 10641.33 | 10670.17 | 10623.00 | 10625.00 | 10563.17 |
Support 2 (S2) | 10604.67 | 10645.16 | 10596.50 | 10554.34 | |
Support 3 (S3) | 10535.33 | 10604.67 | 10545.50 | ||
Support 4 (S4) | 10519.00 |